scispace - formally typeset
V

Vignesh Sounderrajan

Researcher at Madurai Kamaraj University

Publications -  6
Citations -  34

Vignesh Sounderrajan is an academic researcher from Madurai Kamaraj University. The author has contributed to research in topics: Tuberculosis & Medicine. The author has an hindex of 2, co-authored 5 publications receiving 13 citations.

Papers
More filters
Journal ArticleDOI

Structural basis for the inhibition of SARS-CoV2 main protease by Indian medicinal plant-derived antiviral compounds.

TL;DR: It is insisted that the amentoflavone, hypericin and Torvoside H from the traditional Indian medicinal plants may be used as a potential inhibitor of SARS-CoV2 main protease and further biochemical experiments could shed light on understanding the mechanism of inhibition by these plant-derived antiviral compounds.
Book ChapterDOI

Basics of tuberculosis disease and principles of treatment and their effects

TL;DR: In this paper, the authors developed the Directly Observed Treatment, Short-Course (DOTS) protocol for TB, which involves an antiregimen with four drugs: isoniazid (H), rifampin (R), pyrazinamide (Z), and either ethambutol (E) or streptomycin (S) for 2 months.
Journal ArticleDOI

Susceptibility of SARS Coronavirus-2 infection in domestic and wild animals: a systematic review

TL;DR: A review article as mentioned in this paper gives insights on the current knowledge about SARS-CoV-2 infection and development in animals on the farm and in domestic community and their impact on society.
Journal ArticleDOI

Immunoglobulin G1 binding with various molecular receptors: A new paradigm of IgG1 as a potential adjuvant

TL;DR: IgG1 binds to the granulocyte-macrophage receptor, β common receptor and complementary receptor(complementary receptor I and complementary receptors II) to form a complex structure and is shown to have comparable binding efficiency of four receptors to IgG1 apart from the conventional Fc receptor.
Journal ArticleDOI

Current perceptions on advanced molecular diagnostics for drug-resistant mycobacterium tuberculosis

TL;DR: In this paper, the authors used the point-of-care molecular modalities, GeneXpert MTB/RIF and line probe assays focused only on resistance-conferring mutations in specific target hotspot regions, but did not identify novel mutations, outside mutations and they may miss some locally prevalent rifampicin-concerning mutations and not provided a large number of antibiotics/antibiotic groups that are used for DRTB treatment.